Edesa Biotech (NASDAQ:EDSA) | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
Edesa Biotech

BRIEF

published on 06/24/2024 at 14:25, 4 months 26 days ago

BARDA sélectionne le médicament d'Edesa Biotech pour un essai sur plateforme financé par les États-Unis dans le SDRA général

Essai Clinique Edesa Biotechnologie SDRA BARDA Paridiprubart
BRIEF

published on 06/24/2024 at 14:25, 4 months 26 days ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Clinical Trial Edesa Biotech ARDS BARDA Paridiprubart
PRESS RELEASE

published on 06/24/2024 at 14:20, 4 months 26 days ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
Edesa Biotech's paridiprubart selected for BARDA-funded Phase 2 trial to evaluate treatment for ARDS in hospitalized patients. Study to focus on threat-agnostic host-directed therapeutics

Edesa Biotech ARDS Phase 2 Trial Paridiprubart BARDA-funded
BRIEF

published on 05/10/2024 at 22:20, 6 months 10 days ago

Edesa Biotech publie ses résultats du 2e trimestre de l'exercice 2024

Performance Financière Edesa Biotechnologie Études Cliniques Résultats Trimestriels Fiscaux Traitement Du SDRA
BRIEF

published on 05/10/2024 at 22:20, 6 months 10 days ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Financial Performance Edesa Biotech Clinical Studies Fiscal Quarterly Results ARDS Treatment
PRESS RELEASE

published on 05/10/2024 at 22:15, 6 months 10 days ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2024, focusing on its Phase 3 ARDS study, EB05 drug candidate, and strategic plans for respiratory technology and dermatology. The company showcased operational efficiency and prudent capital management

Financial Results Edesa Biotech Inc Phase 3 ARDS Study EB05 Drug Candidate Respiratory Technology
BRIEF

published on 04/11/2024 at 15:05, 7 months 9 days ago

Edesa Biotech confirme sa participation à la conférence des investisseurs Bloom Burton Healthcare 2024

Biopharmaceutique Essais Cliniques Conférence Sur Les Soins De Santé Edesa Biotechnologie Maladies Immuno-inflammatoires
BRIEF

published on 04/11/2024 at 15:05, 7 months 9 days ago

Edesa Biotech Confirms Participation in 2024 Bloom Burton Healthcare Investor Conference

Immuno-inflammatory Diseases Clinical Trials Biopharmaceutical Edesa Biotech Healthcare Conference
PRESS RELEASE

published on 04/11/2024 at 15:00, 7 months 9 days ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech, Inc. (NASDAQ:EDSA) to participate in Bloom Burton & Co. Healthcare Investor Conference, with CEO Par Nijhawan presenting. Company focuses on host-directed therapeutics for immuno-inflammatory diseases

Immuno-inflammatory Diseases EB05 Edesa Biotech NASDAQ:EDSA Bloom Burton & Co. Healthcare Investor Conference
BRIEF

published on 04/02/2024 at 15:05, 7 months 18 days ago

Edesa Biotech participera aux prochaines conférences d'investisseurs

Immunothérapie Essais Cliniques Produits Biopharmaceutiques Edesa Biotechnologie Conférences Investisseurs

1 2 ... 5

Accesswire

Published on 11/21/2024 at 09:00, 34 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 8 hours 59 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 9 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 34 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 34 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 32 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 34 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 34 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 18 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 24 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 36 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 36 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 36 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 26 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 14 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE